Practical implication
Integrate new protocols for screening and dosage adjustments for fluoropyrimidines in all healthcare establishments, alongside increased monitoring of DPD screening outcomes within pharmacovigilance processes.
Following a national investigation into healthcare facilities, the French health authority (ANSM) has implemented measures that enhance the safety of patients undergoing chemotherapy with fluoropyrimidines. Key actions include mandatory dihydropyrimidine dehydrogenase (DPD) deficit screening prior to treatment and establishment of expert recommendations for dosage adjustments based on uracilemia levels.
What changed: Mandatory screening for DPD deficit through uracil level measurement before initiating fluoropyrimidine therapy, applicable to all healthcare facilities administering such treatments.
Why it matters: These measures aim to reduce adverse effects linked to fluoropyrimidine chemotherapy by ensuring appropriate patient screening and dosage adjustments, ultimately enhancing patient safety.
Practical implication: Integrate new protocols for screening and dosage adjustments for fluoropyrimidines in all healthcare establishments, alongside increased monitoring of DPD screening outcomes within pharmacovigilance processes.
View original source
- Source: ANSM (France) - News feed
- Published at source: 2026-09-09T00:00:00.000Z
- Discovered by monitor: 2026-09-09T21:45:30.492Z
Published from the regulator source ingestion pipeline after PV impact triage.
